Hirt, Julian http://orcid.org/0000-0001-6589-3936
Dembowska, Kinga http://orcid.org/0000-0001-6903-2826
Woelfle, Tim http://orcid.org/0000-0001-6279-4158
Axfors, Cathrine http://orcid.org/0000-0002-2706-1730
Granziera, Cristina http://orcid.org/0000-0002-4917-8761
Kuhle, Jens http://orcid.org/0000-0002-6963-8892
Kappos, Ludwig http://orcid.org/0000-0003-4175-5509
Hemkens, Lars G. http://orcid.org/0000-0002-3444-1432
Janiaud, Perrine http://orcid.org/0000-0001-7684-8014
Funding for this research was provided by:
University of Basel
Article History
Received: 16 February 2024
Revised: 28 March 2024
Accepted: 30 March 2024
First Online: 16 April 2024
Change Date: 19 May 2024
Change Type: Update
Change Details: Supplementary file has been replaced
Declarations
:
: Julian Hirt declares no competing interests. RC2NB (Research Center for Clinical Neuroimmunology and Neuroscience Basel) is supported by Foundation Clinical Neuroimmunology and Neuroscience Basel. Kinga Dembowska declares no competing interests. RC2NB (Research Center for Clinical Neuroimmunology and Neuroscience Basel) is supported by Foundation Clinical Neuroimmunology and Neuroscience Basel. Tim Woelfle declares no competing interests. RC2NB (Research Center for Clinical Neuroimmunology and Neuroscience Basel) is supported by Foundation Clinical Neuroimmunology and Neuroscience Basel. Cathrine Axfors declares no competing interests. RC2NB (Research Center for Clinical Neuroimmunology and Neuroscience Basel) is supported by Foundation Clinical Neuroimmunology and Neuroscience Basel. Cristina Granziera: The University Hospital Basel (USB), as the employer of Cristina Granziera has received the following fees which were used exclusively for research support: (i) advisory board and consultancy fees from Actelion, Novartis, Genzyme and F. Hoffmann-La Roche; (ii) speaker fees from Biogen and Genzyme-Sanofi; (iii) research support by F. Hoffmann-La Roche Ltd. Before my employment at USB, I have also received speaker honoraria and travel funding by Novartis. Jens Kuhle received speaker fees, research support, travel support, and/or served on advisory boards by the Progressive MS Alliance, Swiss MS Society, Swiss National Research Foundation (320030_189140 / 1), University of Basel, Biogen, Celgene, Merck, Novartis, Octave Bioscience, Roche, Sanofi. Ludwig Kappos has received no personal compensation. His institutions (University Hospital Basel/Stiftung Neuroimmunology and Neuroscience Basel) have received and used exclusively for research support payments for steering committee and advisory board participation, consultancy services, and participation in educational activities from: Actelion, Bayer, BMS, df-mp Molnia & Pohlmann, Celgene, Eli Lilly, EMD Serono, Genentech, Glaxo Smith Kline, Janssen, Japan Tobacco, Merck, MH Consulting, Minoryx, Novartis, F. Hoffmann-La Roche Ltd, Senda Biosciences Inc., Sanofi, Santhera, Shionogi BV, TG Therapeutics, and Wellmera, and license fees for Neurostatus-UHB products; grants from Novartis, Innosuisse, and Roche. Lars G. Hemkens has no competing interests. RC2NB (Research Center for Clinical Neuroimmunology and Neuroscience Basel) is supported by Foundation Clinical Neuroimmunology and Neuroscience Basel. Perrine Janiaud declares no competing interests. RC2NB (Research Center for Clinical Neuroimmunology and Neuroscience Basel) is supported by Foundation Clinical Neuroimmunology and Neuroscience Basel.
: Not applicable.
: Not applicable.